Curing Patients Isn’t Profitable-Big Pharma Exposed-Hep C Cure Quashed

A 2015 Hepatitis C cure by Gilead Sciences slashed patient numbers—and profits dropped 70%. A Goldman Sachs report bluntly questioned if curing patients is a “sustainable business model,” exposing a hard truth: Big Pharma prioritizes profits over permanent solutions. The industry thrives on chronic illness, not cures—keeping patients dependent and cash flowing.
Source-
🇺🇸Join👉 @SGTnewsNetwork
📎  Twitter  ▪️ Truth Social